MYGN · Myriad Genetics Inc · Executive Compensation
$6.63
+0.00 (+0.00%)
At close · Oct 29
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$634.16M
Shares
95.65M
Volume · Oct 29
414.26K
Avg daily vol (3M)
2.63M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mark Capone | Former President and Chief Executive Officer and Director | $6,174,458 |
| R. Bryan Riggsbee Chief | Financial Officer and Treasurer; Interim President and Chief Executive Officer | $4,203,341 |
| Alexander Ford | Former Chief Operating Officer | $2,183,043 |
| Gary A. King | Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement | $1,961,159 |
| Bernard F. Tobin | Former President of Myriad Autoimmune | $1,879,045 |
| Jerry S. Lanchbury | Chief Scientific Officer | $1,829,238 |
| Nicole Lambert | Group President of Myriad | $1,704,706 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark Capone | Former President and Chief Executive Officer and Director | $8,896,684 |
| Alexander Ford | Former Chief Operating Officer | $3,231,702 |
| R. Bryan Riggsbee Chief | Financial Officer and Treasurer; Interim President and Chief Executive Officer | $3,138,983 |
| Jerry S. Lanchbury | Chief Scientific Officer | $2,685,750 |
| Bernard F. Tobin | Former President of Myriad Autoimmune | $2,341,508 |
| Gary A. King | Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement | $2,105,155 |
| Women’s Health | Oncology, and International | $993,788 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Mark Capone | Former President and Chief Executive Officer and Director | $7,054,950 |
| Alexander Ford | Former Chief Operating Officer | $2,760,945 |
| R. Bryan Riggsbee Chief | Financial Officer and Treasurer; Interim President and Chief Executive Officer | $2,645,582 |
| Jerry S. Lanchbury | Chief Scientific Officer | $2,377,676 |
| Bernard F. Tobin | Former President of Myriad Autoimmune | $1,939,681 |
| Gary A. King | Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement | $1,858,183 |
| Women’s Health | Oncology, and International | $703,269 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Brian Donnelly | Chief Commercial Officer | Resigned | 2026-10-09 |
| Vishal Sikri | Executive Vice President, Commercial | Appointed | 2026-09-16 |
| Daniel M. Skovronsky M.D., Ph.D. | member of the Board of Directors | Resigned | 2026-06-23 |
| Lee N. Newcomer, M.D. | Class III director | Appointed | 2026-06-04 |
| Rashmi Kumar | Class III director | Appointed | 2026-06-04 |
| Paul M. Bisaro | Class III director | Appointed | 2026-06-04 |
| Scott J. Leffler | Chief Financial Officer | Resigned | 2025-10-07 |
| Natalie Munk | Senior Vice President, Chief Accounting Officer and principal accounting officer | Resigned | 2025-10-03 |
| Ben R. Wheeler | Chief Financial Officer | Appointed | 2025-08-18 |
| Colleen F. Reitan | director | Appointed | 2025-06-05 |
| Heiner Dreismann, PH.D. | director | Appointed | 2025-06-05 |
| Samraat S. Raha | director | Appointed | 2025-06-05 |
| Sam Raha | member of the Board | Appointed | 2025-02-24 |
| Sam Raha | President and Chief Executive Officer (CEO) | Appointed | 2025-02-24 |
| Mark S. Verratti | Chief Operating Officer | Appointed | 2025-02-24 |
| Samraat S. Raha | President and Chief Executive Officer | Appointed | 2025-02-24 |
| Samraat S. Raha | Class II director | Appointed | 2025-02-24 |
| Paul J. Diaz | Director | Resigned | 2025-02-24 |
| Paul J. Diaz | President and Chief Executive Officer | Resigned | 2025-02-24 |
| Mark S. Davis | Class I Director | Appointed | 2024-12-10 |
| Scott J. Leffler | Chief Financial Officer and principal financial officer | Appointed | 2023-12-21 |
| Samraat S. Raha | Chief Operating Officer | Appointed | 2023-11-01 |
| Nicole Lambert | Chief Operating Officer | Resigned | 2023-10-05 |
| Rashmi Kumar | director | Appointed | 2023-06-02 |
| Lee N. Newcomer, M.D. | director | Appointed | 2023-06-02 |
Leadership
- R. Bryan Riggsbee CEO
- R. Bryan Riggsbee Chief CEO
- Sam Raha CEO, Board Member
- Samraat Raha CEO, COO, Board Member
- Samraat S. Raha CEO, Board Member
- Ben R. Wheeler CFO
- Benjamin R. Wheeler CFO
- Bryan Riggsbee CFO
- Scott Leffler CFO
- Mark S. Verratti COO
- Mark Verratti COO
- Kevin R. Haas CTO
- Benjamin G. Jackson General Counsel
- Colleen F. Reitan Board Member
- Continuing Directors Board Member
- Daniel M. Skovronsky, M.D. Ph.D. Board Member
- Daniel Spiegelman Board Member
- Dennis H. Langer Board Member
- Heiner Dreismann Board Member
- Heiner Dreismann, PH.D. Board Member
- Lee N. Newcomer Board Member
- Lee N. Newcomer M.D. Board Member
- Lee N. Newcomer, M.D Board Member
- Lee N. Newcomer, M.D. Board Member
- Mark S. Davis Board Member
- Paul M. Bisaro Board Member
- Rashmi Kumar Board Member
Key facts
CIK
899923
CUSIP
62855J104
13F (30d)
25 filings
25 filers
Visit website
Investor relations